A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell.

An emerging class of anticancer drugs called EZH2 inhibitors may greatly ... found that EZH2 inhibition combined with T-cell based immunotherapy worked better at shrinking non-Hodgkin B-cell ...